Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Cohen & Steers, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to institutional investors, including pension funds, endowments, and foundations. It manages separate client-focused equity, fixed income, multi-asset, and commodity portfolios through its subsidiaries. The firm launches and manages equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. Through its subsidiaries, it also launches and manages hedge funds. The firm invests in public equity, fixed income, and commodity markets across the globe through its subsidiaries. Through its subsidiaries, it invests in companies operating in the real estate sector, including real estate investment trusts, infrastructure sector, and natural energy resources sector for its equity and fixed income investments. The firm also invests in preferred securities for its fixed income investments through its subsidiaries. Cohen & Steers, Inc. was founded in 1986 and is based in New York, with additional offices in London, United Kingdom; Central, Hong Kong; Tokyo, Japan; and Seattle, Washington.

Cohen & Steers, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DALLAS--(BUSINESS WIRE)--LANTERN PHARMA AND STARLIGHT THERAPEUTICS ANNOUNCE FDA CLEARANCE OF IND FOR A PLANNED PHASE 1 PEDIATRIC CNS CANCER TRIAL OF STAR-001.

LANTERN PHARMA AND STARLIGHT THERAPEUTICS ANNOUNCE FDA CLEARANCE OF IND FOR A PLANNED PHASE 1 PEDIATRIC CNS CANCER TRIAL OF STAR-001

SACRAMENTO, CALIF., MARCH 26, 2026 /PRNEWSWIRE/ -- LUNAI BIOWORKS, INC. (NASDAQ: LNAI) TODAY ANNOUNCED IT HAS EXECUTED A BINDING $20 MILLION STRATEGIC TRANSACTION TO ACQUIRE BLOOD-BRAIN BARRIER (BBB) DELIVERY TECHNOLOGY AND CENTRAL NERVOUS SYSTEM (CNS) ALZHEIMER'S DRUG ASSETS FROM THE CLEMANN GROUP, SAS OR ITS ASSIGNEE.

LUNAI BIOWORKS EXECUTES $20M STRATEGIC TRANSACTION AT FIXED $1.50 CONVERSION, ACQUIRING BBB DELIVERY PLATFORM FOR CNS ALZHEIMER'S THERAPIES WITH BROAD CNS DELIVERY APPLICATIONS

NEW YORK, MARCH 24, 2026 /PRNEWSWIRE/ -- THE BOARD OF DIRECTORS OF THE COHEN & STEERS CLOSED-END FUNDS ANNOUNCED TODAY THE MONTHLY DISTRIBUTIONS FOR APRIL, MAY AND JUNE 2026, AS SUMMARIZED IN THE CHARTS BELOW: TICKER FUND NAME MONTHLYDIVIDEND FOF COHEN & STEERS CLOSED-END OPPORTUNITY FUND, INC. $0.087 LDP COHEN & STEERS LIMITED DURATION PREFERRED AND INCOME FUND, INC. $0.131 PSF COHEN & STEERS SELECT PREFERRED AND INCOME FUND, INC. $0.126 PTA COHEN & STEERS TAX-ADVANTAGED PREFERRED SECURITIES AND INCOME FUND $0.134 RFI COHEN & STEERS TOTAL RETURN REALTY FUND, INC. $0.080 RLTY COHEN & STEERS REAL ESTATE OPPORTUNITIES AND INCOME FUND $0.110 RNP COHEN & STEERS REIT AND PREFERRED AND INCOME FUND, INC. $0.136 RQI COHEN & STEERS QUALITY INCOME REALTY FUND, INC. $0.090 UTF COHEN & STEERS INFRASTRUCTURE FUND, INC. $0.165 DISTRIBUTIONS WILL BE MADE ON THE FOLLOWING SCHEDULE: MONTH EX-DIVIDEND/ RECORD DATE PAYABLE DATE APRIL APRIL 14, 2026 APRIL 30, 2026 MAY MAY 12, 2026 MAY 29, 2026 JUNE JUNE 9, 2026 JUNE 30, 2026 COHEN & STEERS INFRASTRUCTURE FUND, INC. HAS INCREASED ITS MONTHLY DISTRIBUTION BY $0.010 PER SHARE, TO $0.165 PER SHARE. THE FUND'S MONTHLY DISTRIBUTION HAS BEEN ADJUSTED TO REFLECT CURRENT MARKET CONDITIONS.

COHEN & STEERS CLOSED-END FUNDS DECLARE DISTRIBUTIONS FOR APRIL, MAY AND JUNE 2026

MOUNTAIN VIEW, CALIF.--(BUSINESS WIRE)---- $ANRO #CNS--ALTO NEUROSCIENCE, INC. (ALTO) (NYSE: ANRO) A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF NOVEL PRECISION MEDICINES FOR NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED THAT MEMBERS OF THE COMPANY'S MANAGEMENT TEAM WILL PARTICIPATE IN A VIRTUAL FIRESIDE CHAT AT THE STIFEL 2026 VIRTUAL CNS FORUM ON MARCH 17, 2026 AT 12:00PM ET. THE PRESENTATION WILL BE ACCESSIBLE VIA A LIVE WEBCAST ON THE EVENTS AND PRESENTATIONS PAGE IN THE INVESTO.

ALTO NEUROSCIENCE ANNOUNCES PARTICIPATION AT THE STIFEL 2026 VIRTUAL CNS FORUM

SAN DIEGO--(BUSINESS WIRE)--ACADIA PHARMACEUTICALS INC. (NASDAQ: ACAD) TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE STIFEL 2026 VIRTUAL CNS FORUM ON TUESDAY, MARCH 17, 2026 AT 8:00 A.M. EASTERN TIME. A LIVE WEBCAST OF ACADIA'S FIRESIDE CHAT WILL BE ACCESSIBLE ON THE COMPANY'S WEBSITE, ACADIA.COM, UNDER THE INVESTORS SECTION AND AN ARCHIVED RECORDING WILL BE AVAILABLE ON THE WEBSITE FOR APPROXIMATELY ONE MONTH FOLLOWING THE PRESENTATION. ABOUT ACADIA PHARMACEUTICALS ACADIA.

ACADIA PHARMACEUTICALS TO PARTICIPATE IN THE STIFEL 2026 VIRTUAL CNS FORUM

WALTHAM, MASS.--(BUSINESS WIRE)--KORSANA BIOSCIENCES, INC. (KORSANA OR THE COMPANY), A BIOTECHNOLOGY COMPANY DISCOVERING AND DEVELOPING NOVEL THERAPIES TO REDUCE THE BURDEN OF NEURODEGENERATIVE DISEASES, TODAY ANNOUNCED THAT JONATHAN VIOLIN, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER, WILL PRESENT AT THE STIFEL 2026 VIRTUAL CNS FORUM ON TUESDAY, MARCH 17, 2026 AT 3:00 PM ET. A LIVE WEBCAST OF THE COMPANY PRESENTATION WILL BE AVAILABLE ON THE COMPANY'S WEBSITE AT WWW.KORSANA.COM. A REPLAY.

KORSANA BIOSCIENCES TO PRESENT AT THE STIFEL 2026 VIRTUAL CNS FORUM

MIAMI & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--LG CNS CO., LTD. AND PALANTIR TECHNOLOGIES INC. (NASDAQ: PLTR), A LEADING PROVIDER OF AI OPERATING SYSTEMS, TODAY ANNOUNCED A DEEPENED STRATEGIC PARTNERSHIP AIMED AT ACCELERATING AI TRANSFORMATION (AX) INITIATIVES ACROSS LG GROUP. THE ANNOUNCEMENT WAS MADE AHEAD OF PALANTIR'S AIPCON, WHERE THE TWO COMPANIES FORMALIZED THEIR JOINT AMBITION TO BRING TRANSFORMATIONAL BUSINESS IMPACT TO THE DIVERSE PORTFOLIO OF COMPANIES WITHIN ONE OF THE WORLD'S LARGEST.

LG CNS AND PALANTIR ANNOUNCE STRATEGIC PARTNERSHIP TO ACCELERATE AI TRANSFORMATION

NEW YORK, MARCH 11, 2026 /PRNEWSWIRE/ -- COHEN & STEERS, INC. (NYSE: CNS) TODAY ANNOUNCED PLANS TO CONVERT THE COHEN & STEERS FUTURE OF ENERGY FUND, A U.S. MUTUAL FUND DESIGNED TO CAPITALIZE ON OPPORTUNITIES ACROSS TRADITIONAL AND ALTERNATIVE ENERGY, INTO AN ACTIVELY MANAGED EXCHANGE-TRADED FUND ("ETF"). THE ETF WILL BE MANAGED BY THE SAME PORTFOLIO MANAGEMENT TEAM AND PURSUE THE SAME INVESTMENT OBJECTIVES AS THE CURRENT MUTUAL FUND.

COHEN & STEERS ANNOUNCES PLAN TO CONVERT THE COHEN & STEERS FUTURE OF ENERGY FUND TO ETF

NEWLY FORMED EXECUTIVE TEAM INITIATES GLOBAL SEARCH FOR DIFFERENTIATED THERAPEUTIC ASSETS FOR NEUROLOGY AND ONCOLOGY INDICATIONS, TWO OF BIOPHARMA'S LARGEST AND FASTEST-GROWING MARKETS STRATEGIC TRANSFORMATION DRIVEN BY A COMPREHENSIVE DATA ANALYSIS WILL ENABLE NEW EXECUTIVE TEAM TO LEVERAGE DECADES OF EXPERIENCE IN THESE THERAPEUTIC AREAS COMPANY PIVOTING FROM A SINGULAR FOCUS ON GLIOBLASTOMA AND WILL EXPLORE OUT-LICENSING OF LEGACY ASSETS BERUBICIN AND TPI 287 HOUSTON, TX / ACCESS NEWSWIRE / MARCH 11, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) (THE "COMPANY"), A BIOTECHNOLOGY COMPANY FOCUSED ON BUILDING A PIPELINE OF INNOVATIVE THERAPIES IN HIGH-VALUE NEUROLOGY AND ONCOLOGY MARKETS, TODAY ANNOUNCED THAT IT HAS LAUNCHED A NEW CORPORATE GROWTH STRATEGY DESIGNED TO BUILD A HIGH-VALUE PIPELINE IN NEUROLOGY AND ONCOLOGY. THE STRATEGY IS BEING LED BY THE NEWLY FORMED EXECUTIVE TEAM WITH DEEP EXPERIENCE ACROSS NEUROLOGY, ONCOLOGY AND RARE DISEASE DRUG DEVELOPMENT.

CNS PHARMACEUTICALS LAUNCHES NEW CORPORATE STRATEGY FOCUSED ON BUILDING A HIGH-VALUE NEUROLOGY AND ONCOLOGY PIPELINE

SARASOTA, FLA., MARCH 11, 2026 (GLOBE NEWSWIRE) -- ORAGENICS, INC. (NYSE AMERICAN: OGEN), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY PIONEERING BRAIN-TARGETED THERAPEUTICS THROUGH PROPRIETARY INTRANASAL DELIVERY TECHNOLOGY, TODAY ANNOUNCED THAT IT IS EXPLORING DISCUSSIONS WITH THIRD PARTIES REGARDING THE POTENTIAL ACQUISITION OF ADDITIONAL ASSETS IN THE CENTRAL NERVOUS SYSTEM (CNS) SPACE, WITH A SPECIFIC FOCUS ON BRAIN HEALTH AND BRAIN RECOVERY INDICATIONS THAT DEMONSTRATE STRATEGIC SYNERGIES WITH THE COMPANY'S LEAD CANDIDATE ONP-002 AND ITS PROPRIETARY INTRANASAL DRUG DELIVERY PLATFORM.

ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

SAN DIEGO, MARCH 10, 2026 /PRNEWSWIRE/ -- NEUROCRINE BIOSCIENCES, INC. (NASDAQ: NBIX) TODAY ANNOUNCED THAT MEMBERS OF THE MANAGEMENT TEAM WILL PARTICIPATE AT THE STIFEL 2026 VIRTUAL CNS FORUM AT 4:30 PM EST ON MARCH 17, 2026. THE LIVE WEBCAST CAN BE ACCESSED ON NEUROCRINE BIOSCIENCES' WEBSITE UNDER INVESTORS AT WWW.NEUROCRINE.COM.

NEUROCRINE BIOSCIENCES TO PRESENT AT THE STIFEL 2026 VIRTUAL CNS FORUM

NEWTON, MASS., MARCH 10, 2026 (GLOBE NEWSWIRE) -- ACUMEN PHARMACEUTICALS, INC. (NASDAQ: ABOS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS THAT TARGET TOXIC SOLUBLE AMYLOID BETA OLIGOMERS FOR THE TREATMENT OF ALZHEIMER'S DISEASE, ANNOUNCED TODAY THAT MANAGEMENT WILL PARTICIPATE IN A FIRESIDE CHAT AT THE STIFEL 2026 VIRTUAL CNS FORUM ON WEDNESDAY, MARCH 18, 2026, AT 11:00 A.M. ET.

ACUMEN PHARMACEUTICALS TO PARTICIPATE IN THE STIFEL 2026 VIRTUAL CNS FORUM

NEW YORK, MARCH 9, 2026 /PRNEWSWIRE/ -- COHEN & STEERS, INC. (NYSE: CNS) TODAY REPORTED PRELIMINARY ASSETS UNDER MANAGEMENT OF $98.4 BILLION AS OF FEBRUARY 28, 2026, AN INCREASE OF $5.4 BILLION FROM ASSETS UNDER MANAGEMENT OF $93.1 BILLION AT JANUARY 31, 2026. THE INCREASE WAS DUE TO MARKET APPRECIATION OF $5.5 BILLION AND NET INFLOWS OF $7 MILLION, PARTIALLY OFFSET BY DISTRIBUTIONS OF $151 MILLION.

COHEN & STEERS ANNOUNCES PRELIMINARY ASSETS UNDER MANAGEMENT AND NET FLOWS FOR FEBRUARY 2026

RECOGNITION HIGHLIGHTS GLOBAL SCALE, PERFORMANCE LEADERSHIP, AND SERVICE AVAILABILITY EXPERTISE LONDON, MARCH 5, 2026 /PRNEWSWIRE/ -- CORERO NETWORK SECURITY (AIM: CNS) (OTCQX: DDOSF), A LEADER IN REAL-TIME DDOS PROTECTION AND SERVICE AVAILABILITY, TODAY ANNOUNCED IT HAS BEEN NAMED A "STAR" IN THE MARKETSANDMARKETS DDOS PROTECTION & MITIGATION SECURITY MARKET REPORT. POSITIONED IN THE "STARS" QUADRANT, CORERO EARNED "EXCELLENT" RATINGS ACROSS ALL MAJOR FOOTPRINT CATEGORIES: REGIONAL PRESENCE, OFFERING BREADTH, VERTICAL FOCUS, AND OVERALL EXECUTION.

CORERO NETWORK SECURITY NAMED A 'STAR' IN MARKETSANDMARKETS DDOS PROTECTION & MITIGATION SECURITY MARKET REPORT

DR. KELLEY ADDS TWO DECADES OF HIGHLY RELEVANT DRUG DEVELOPMENT AND REGULATORY STRATEGY EXPERIENCE SPANNING ONCOLOGY, RARE DISEASES AND CNS NEWLY FORMED EXECUTIVE TEAM IS COMMITTED TO EXECUTION AND COMPANY EVOLUTION FOCUSED ON PATIENT AND STAKEHOLDER VALUE HOUSTON, TX / ACCESS NEWSWIRE / MARCH 2, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THE APPOINTMENT OF LYNNE KELLEY, MD, FACS, AS CHIEF MEDICAL OFFICER. DR. KELLEY BRINGS MORE THAN TWO DECADES OF GLOBAL LEADERSHIP EXPERIENCE ACROSS CLINICAL DEVELOPMENT, TRANSLATIONAL MEDICINE AND REGULATORY STRATEGY IN ONCOLOGY, RARE DISEASES, CNS AND MEDICAL DEVICES.

CNS PHARMACEUTICALS APPOINTS LYNNE KELLEY, MD, FACS, AS CHIEF MEDICAL OFFICER, COMPLETING EXECUTIVE LEADERSHIP TEAM

NEW YORK, FEB. 26, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS INFRASTRUCTURE FUND, INC. (NYSE: UTF) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON FEBRUARY 27, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN MARCH 2015, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

COHEN & STEERS INFRASTRUCTURE FUND, INC. (UTF) NOTIFICATION OF SOURCES OF DISTRIBUTION UNDER SECTION 19(A)

NEW YORK, FEB. 26, 2026 /PRNEWSWIRE/ --THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS QUALITY INCOME REALTY FUND, INC. (NYSE:RQI) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON FEBRUARY 27, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2012, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

COHEN & STEERS QUALITY INCOME REALTY FUND, INC. (RQI) NOTIFICATION OF SOURCES OF DISTRIBUTION UNDER SECTION 19(A)

NEW YORK, FEB. 26, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS TOTAL RETURN REALTY FUND, INC. (NYSE: RFI) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON FEBRUARY 27, 2026AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2011, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

COHEN & STEERS TOTAL RETURN REALTY FUND, INC. (RFI) NOTIFICATION OF SOURCES OF DISTRIBUTION UNDER SECTION 19(A)

NEW YORK, FEB. 26, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERS CLOSED-END OPPORTUNITY FUND, INC. (NYSE: FOF) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON FEBRUARY 27, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2021, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

COHEN & STEERS CLOSED-END OPPORTUNITY FUND, INC. (FOF) NOTIFICATION OF SOURCES OF DISTRIBUTION UNDER SECTION 19(A)

NEW YORK, FEB. 26, 2026 /PRNEWSWIRE/ -- THIS PRESS RELEASE PROVIDES SHAREHOLDERS OF COHEN & STEERSREIT AND PREFERRED AND INCOME FUND, INC. (NYSE: RNP) (THE "FUND") WITH INFORMATION REGARDING THE SOURCES OF THE DISTRIBUTION TO BE PAID ON FEBRUARY 27, 2026 AND CUMULATIVE DISTRIBUTIONS PAID FISCAL YEAR-TO-DATE. IN DECEMBER 2017, THE FUND IMPLEMENTED A MANAGED DISTRIBUTION POLICY IN ACCORDANCE WITH EXEMPTIVE RELIEF ISSUED BY THE SECURITIES AND EXCHANGE COMMISSION.

COHEN & STEERS REIT AND PREFERRED AND INCOME FUND, INC. (RNP) NOTIFICATION OF SOURCES OF DISTRIBUTION UNDER SECTION 19(A)

NEW YORK, FEB. 26, 2026 /PRNEWSWIRE/ -- THE BOARD OF DIRECTORS OF COHEN & STEERS, INC. (NYSE:CNS) DECLARED A CASH DIVIDEND FOR THE FIRST QUARTER OF 2026 IN THE AMOUNT OF $0.67 PER SHARE OF COMMON STOCK, REPRESENTING AN 8.1% INCREASE FROM THE $0.62 PER SHARE DIVIDEND LAST QUARTER. THE DIVIDEND IS PAYABLE ON MARCH 19, 2026 TO STOCKHOLDERS OF RECORD AS OF THE CLOSE OF BUSINESS ON MARCH 9, 2026.

COHEN & STEERS, INC. DECLARES QUARTERLY DIVIDEND

NEW MEMBERS OF THE STRENGTHENED LEADERSHIP TEAM ADD DECADES OF OPERATIONAL EXECUTION, PIPELINE OPTIMIZATION AND TRANSACTIONAL EXPERTISE TO SUPPORT COMPANY GROWTH AND VALUE CREATION HOUSTON, TX / ACCESS NEWSWIRE / FEBRUARY 17, 2026 / CNS PHARMACEUTICALS, INC. (NASDAQ:CNSP) ("CNS" OR THE "COMPANY"), A BIOPHARMACEUTICAL COMPANY SPECIALIZING IN THE DEVELOPMENT OF NOVEL TREATMENTS FOR PRIMARY AND METASTATIC CANCERS IN THE BRAIN AND CENTRAL NERVOUS SYSTEM, TODAY ANNOUNCED THE COMPANY'S RECENTLY APPOINTED PRESIDENT AND CHIEF EXECUTIVE OFFICER, RAMI LEVIN, IN CLOSE ALIGNMENT WITH THE BOARD OF DIRECTORS, HAS RECRUITED KEY MEMBERS TO HIS NEW EXECUTIVE TEAM. THESE NEW APPOINTMENTS, WHICH WILL BE EFFECTIVE MARCH 2, 2026, WILL HELP DRIVE THE COMPANY'S EVOLUTION.

CNS PHARMACEUTICALS APPOINTS MULTIPLE KEY EXECUTIVES TO DRIVE COMPANY'S RECENTLY INITIATED STRATEGIC TRANSFORMATION

DELIVERING ALWAYS-ON AVAILABILITY WHERE UPTIME DEFINES REPUTATION LONDON, FEB. 10, 2026 /PRNEWSWIRE/ -- CORERO NETWORK SECURITY (AIM: CNS) (OTCQX: DDOSF), A RECOGNIZED LEADER IN DDOS PROTECTION AND CHAMPION OF ADAPTIVE, REAL-TIME SERVICE AVAILABILITY, TODAY ANNOUNCED A STRATEGIC PARTNERSHIP WITH EDGEUNO, A REGIONAL CONNECTIVITY PROVIDER IN LATIN AMERICA, TO EXPAND AUTOMATED DDOS PROTECTION AS A FULLY MANAGED SERVICE THROUGHOUT THE REGION. THE PARTNERSHIP COMBINES EDGEUNO'S REGIONAL REACH WITH CORERO'S AUTOMATED DEFENSE SYSTEMS TO KEEP SERVICES ONLINE DURING ATTACKS.

CORERO NETWORK SECURITY AND EDGEUNO PARTNER TO SCALE REAL-TIME, AUTOMATED DDOS PROTECTION ACROSS LATIN AMERICA

NEW YORK, FEB. 9, 2026 /PRNEWSWIRE/ -- COHEN & STEERS, INC. (NYSE:CNS) TODAY REPORTED PRELIMINARY ASSETS UNDER MANAGEMENT OF $93.1 BILLION AS OF JANUARY 31, 2026, AN INCREASE OF $2.5 BILLION FROM ASSETS UNDER MANAGEMENT OF $90.5 BILLION AT DECEMBER 31, 2025. THE INCREASE WAS DUE TO MARKET APPRECIATION OF $2.2 BILLION AND NET INFLOWS OF $449 MILLION, PARTIALLY OFFSET BY DISTRIBUTIONS OF $153 MILLION.

COHEN & STEERS ANNOUNCES PRELIMINARY ASSETS UNDER MANAGEMENT AND NET FLOWS FOR JANUARY 2026

VANCOUVER, BRITISH COLUMBIA--(NEWSFILE CORP. - FEBRUARY 9, 2026) - PREVECEUTICAL MEDICAL INC.(CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0)(THE "COMPANY" OR "PREVECEUTICAL")IS PLEASED TO ANNOUNCE IT HAS FILED AN INTERNATIONAL (PCT) PATENT APPLICATION ON FEBRUARY 5, 2026, HAVING THE APPLICATION NO. PCT/US2026/014110, AND ENTITLED "DELIVERY OF CNS-ACTIVE THERAPEUTIC AGENTS".

PREVECEUTICAL ANNOUNCES FILING OF PATENT FOR DELIVERY OF CNS-ACTIVE AGENTS

SAN DIEGO & BOSTON--(BUSINESS WIRE)--SEQSTER, THE LEADING HEALTHCARE TECHNOLOGY COMPANY AND THE DATA CONNECTION, COLLECTION, AND ORCHESTRATION LAYER FOR PATIENT HEALTH DATA, AND PRAXIS PRECISION MEDICINES, INC., TODAY ANNOUNCED THE EXPANSION OF A SUCCESSFUL PARTNERSHIP TO ACCELERATE CLINICAL TRIALS, DATA COLLECTION, AND REAL-WORLD EVIDENCE (RWE) GENERATION ACROSS PRAXIS'S CLINICAL DEVELOPMENT PROGRAMS. BUILDING ON EARLY SUCCESS IN PRAXIS'S INNOVATIVE ESSENTIAL3 PROGRAM FOR ESSENTIAL TREMOR, SEQ.

Cohen & Steers, Inc.

CNS

Price

Financial Reports

No items found.

Press Releases

Cohen & Steers, Inc.

CNS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

CNS